• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Adalimumab aids in control of noninfectious uveitis

byDayton McMillanandShaidah Deghan, MSc. MD
September 9, 2016
in Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with noninfectious intermediate or posterior uveitis or panuveitis had their symptoms controlled for longer on adalimumab treatment compared to placebo.

2. Patients treated with adalimumab had more adverse events and serious adverse events compared to the placebo treated group.

Evidence Rating: 1 (Excellent)

Study Rundown: Noninfectious uveitis is a group of conditions that can manifest alone or as part of various systemic disorders. If untreated or uncontrolled it can put one’s vision at risk. Current medical therapy for noninfectious uveitis often includes glucocorticoids, which can cause various undesired effects. Tumor necrosis factor alpha (TNF-α) is considered active in uveitis inflammation, so the anti–TNF-α monoclonal antibody Adalimumab has been considered as a potential agent for glucocorticoid-sparing noninfectious uveitis control. This study was conducted to evaluate the efficacy and safety of this treatment.

Patients with active noninfectious intermediate or posterior uveitis of panuveitis despite prior glucocorticoid treatment were included in the study. Participants received either adalimumab or placebo. The primary endpoint of the study was treatment failure (return of specific uveitis symptoms or uveitis markers) after 6 weeks. Patients in the adalimumab group had a median time to treatment failure of 24 weeks while that of the placebo group was 13 weeks. Those in the adalimumab group were also less likely to reach treatment failure compared to the placebo group. Adverse events were more common in the adalimumab group, as were serious adverse events.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis

2 Minute Medicine Rewind July 14, 2025

New obesity framework may reclassify over half of overweight individuals as people with obesity

Relevant Reading: The role of tumor necrosis factor (TNF-alpha) in experimental autoimune uveoretinitis (EAU)

In-Depth [randomized control trial]: This phase 3 international trail was conducted at multiple sites from August 2010 to August 2014. Patients with active noninfectious uveitis who were nonresponsive to prior glucocorticoid treatment were divided in a 1:1 ratio between treatment (abalimumab, n = 110) and placebo (n = 107) groups, and stratified by glucocorticoid treatment at baseline. Adalimumab was given at baseline (80 mg) and every 2 weeks from week 1 onwards (40 mg) and delivered subcutaneously. At baseline all patients were given prednisone (60 mg) and were tapered on a standardized schedule. Follow-up visits with patients to document their uveitis occurred at weeks 0, 1, 4, 6, 8, and approximately every subsequent 4 weeks. The primary endpoint of the study was treatment failure after week 6, defined by recurrence of various uveitis signs and/or symptoms. Patients were monitored for side effects from the beginning of the study to 70 days after their last treatment or placebo. Median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group. Treated patients were less likely to reach treatment failure compared to the placebo group (HR 0.50; 95%CI 0.36 to 0.70; p < 0.001). This finding did not prove to be true among patients with birdshot choroidopathy (HR 0.49; 95%CI 0.21 to 1.14; p = 0.09).

Increase in vitreous haze grade was the reason for treatment failure in 36% of the placebo group and 15% of the treatment group. The adalimumab group had more adverse events (1052.4 vs. 971.7) and serious adverse events (28.8 vs. 13.6) per 100 person-years.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Current therapies ineffective at reducing epistaxis in hereditary hemorrhagic telangiectasia

Next Post

The SCD-HeFT: ICD vs. amiodarone for congestive heart failure [Classics Series]

RelatedReports

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
StudyGraphics

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis

July 14, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Weekly Rewinds

2 Minute Medicine Rewind July 14, 2025

July 14, 2025
Colonic byproduct may decrease long-term weight gain
Public Health

New obesity framework may reclassify over half of overweight individuals as people with obesity

July 14, 2025
Patients with advanced adenomas are at increased risk of developing colorectal cancer
Chronic Disease

Digital health apps may have limited role in reduction of migraine symptoms

July 13, 2025
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The SCD-HeFT: ICD vs. amiodarone for congestive heart failure [Classics Series]

An analysis of soccer-related injuries in emergency departments

An analysis of soccer-related injuries in emergency departments

High error rate among parents measuring liquid medications

High error rate among parents measuring liquid medications

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
  • 2 Minute Medicine Rewind July 14, 2025
  • New obesity framework may reclassify over half of overweight individuals as people with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.